News & Updates
Showing Multidisciplinary articles
Showing
Sotorasib demonstrates durable efficacy in KRASG12C-mutated NSCLC
The KRASG12C inhibitor sotorasib has demonstrated durable efficacy in patients with locally advanced or metastatic KRASG12C-mutated non-small-cell lung cancer (NSCLC), with 2-year overall survival (OS) reported in one-third of patients in the CodeBreaK 100 trial.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
Musculoskeletal pain common in T2D but does not influence treatment goals
Musculoskeletal pain is a common coexisting symptom in patients with type 2 diabetes (T2D), with most patients having knee or lower back pain, a study reports. However, despite the major disability burden associated with these types of pain, it does not seem to get in the way of achieving treatment targets.
Rectal evacuation disorders tied to poor bowel preparation in chronic constipation patients
Outlet dysfunction is associated with suboptimal bowel preparation and decreased cecal intubation, among others, in patients with chronic constipation undergoing colonoscopy, reveals a study.
How does IV edaravone fare for ALS in the real world?
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
Combination treatment with trabectedin and durvalumab appears to be promising in the treatment of patients with platinum-refractory ovarian carcinoma, shrinking tumour while having a manageable side effect profile, according to data from the phase Ib TRAMUNE trial.